Insmed (NASDAQ:INSM) Stock Crosses Below 50 Day Moving Average – Should You Sell?

Insmed, Inc. (NASDAQ:INSM)’s stock price crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $112.33 and traded as low as $109.22. Insmed shares last traded at $109.31, with a volume of 4,240,345 shares.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on INSM shares. Wolfe Research downgraded shares of Insmed from an “outperform” rating to a “peer perform” rating in a report on Monday, October 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Thursday, October 15th. JPMorgan Chase & Co. decreased their target price on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, August 10th. Benchmark reiterated a “buy” rating on shares of Insmed in a research note on Monday. Finally, Stifel Nicolaus set a $195.00 price target on shares of Insmed in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Insmed has an average rating of “Moderate Buy” and a consensus target price of $196.52.

Insmed Stock Performance

The stock has a market capitalization of $23.87 billion, a P/E ratio of -38.76 and a beta of 0.83. The stock has a 50 day simple moving average of $112.33 and a two-hundred day simple moving average of $125.41. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The company had revenue of $524.43 million for the quarter, compared to the consensus estimate of $500.36 million. During the same quarter in the prior year, the company earned ($1.75) EPS. The company’s revenue for the quarter was up 268.4% on a year-over-year basis. On average, equities analysts forecast that Insmed, Inc. will post -1.62 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, COO Roger Adsett sold 239,850 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the transaction, the chief operating officer directly owned 98,744 shares in the company, valued at approximately $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Brennan sold 25,000 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the transaction, the director owned 39,238 shares in the company, valued at approximately $4,865,512. The trade was a 38.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in Insmed during the 2nd quarter worth approximately $139,966,000. Assenagon Asset Management S.A. boosted its stake in Insmed by 480.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company’s stock valued at $144,591,000 after purchasing an additional 1,048,518 shares during the period. Railway Pension Investments Ltd acquired a new position in Insmed in the 2nd quarter valued at $64,473,000. Sei Investments Co. grew its holdings in Insmed by 56.8% in the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock valued at $228,239,000 after buying an additional 505,624 shares in the last quarter. Finally, SEB Asset Management AB acquired a new position in Insmed in the 1st quarter valued at $27,075,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.